Search research articles
Contact Us
Filters
Showing results (431-440 of 448) with videos related to
Page
of 45
Sort By:
The Journal of Infectious Diseases
|
August 2, 2015
Development of Prototype Filovirus Recombinant Antigen Immunoassays
Matt L Boisen, Darin Oottamasathien, Abigail B Jones, et al.
The Journal of Infectious Diseases
|
September 3, 2016
Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection
Robert W Cross, Matthew L Boisen, Molly M Millett, et al.
Ebiomedicine
|
March 29, 2025
Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials
Christopher L Cooper, Gavin Morrow, Maoli Yuan, et al.
NPJ Vaccines
|
May 3, 2026
Searching for immune correlates in Lassa vaccine development - workshop report
Trevor Brasel, Polina Brangel, Ifedayo Adetifa, et al.
Plos Pathogens
|
October 13, 2022
An introduction to the Marburg virus vaccine consortium, MARVAC
Robert W Cross, Ira M Longini, Stephan Becker, et al.
Scientific Reports
|
April 14, 2018
Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever
Matthew L Boisen, Jessica N Hartnett, Jeffrey G Shaffer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 28, 2019
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
N W Clarke, A Ali, F C Ingleby, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 13, 2018
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
M R Sydes, M R Spears, M D Mason, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2020
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003
N W Clarke, A Ali, F C Ingleby, et al.
Scientific Reports
|
September 30, 2020
Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages
Megan L Heinrich, Matthew L Boisen, Diana K S Nelson, et al.
Page
of 45
Search research articles
Search
Showing results (431-440 of 448) with videos related to
Sort By:
Page
of 45
The Journal of Infectious Diseases
|
August 2, 2015
Development of Prototype Filovirus Recombinant Antigen Immunoassays
Matt L Boisen, Darin Oottamasathien, Abigail B Jones, et al.
The Journal of Infectious Diseases
|
September 3, 2016
Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection
Robert W Cross, Matthew L Boisen, Molly M Millett, et al.
Ebiomedicine
|
March 29, 2025
Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials
Christopher L Cooper, Gavin Morrow, Maoli Yuan, et al.
NPJ Vaccines
|
May 3, 2026
Searching for immune correlates in Lassa vaccine development - workshop report
Trevor Brasel, Polina Brangel, Ifedayo Adetifa, et al.
Plos Pathogens
|
October 13, 2022
An introduction to the Marburg virus vaccine consortium, MARVAC
Robert W Cross, Ira M Longini, Stephan Becker, et al.
Scientific Reports
|
April 14, 2018
Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever
Matthew L Boisen, Jessica N Hartnett, Jeffrey G Shaffer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 28, 2019
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
N W Clarke, A Ali, F C Ingleby, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 13, 2018
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
M R Sydes, M R Spears, M D Mason, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2020
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003
N W Clarke, A Ali, F C Ingleby, et al.
Scientific Reports
|
September 30, 2020
Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages
Megan L Heinrich, Matthew L Boisen, Diana K S Nelson, et al.
Page
of 45